Qiang Ping, Pan Qing, Fang Chao, Fozza Claudio, Song Kaidi, Dai Yuanyuan, Chang Wenjiao, Chen Wei, Yao Wan, Zhu Weibo, Liu Xin, Ma Xiaoling
School of Medicine, Shandong University, Jinan, 250100, China.
Department of Hematology, The First Affiliated Hospital of University of Science and Technology of China, Hefei, 230001, China.
Mediterr J Hematol Infect Dis. 2020 Mar 1;12(1):e2020012. doi: 10.4084/MJHID.2020.012. eCollection 2020.
Micro (mi) RNAs play an important role in the pathogenesis and development of acute myeloid leukemia (AML), and their abnormal expression may be sufficient to predict the prognosis and outcomes in AML patients. We evaluated the clinical diagnostic value of miRNA-181a-3p in predicting prognosis and outcomes in patients with AML.
A total of 119 newly diagnosed adult patients with AML and 60 healthy controls were recruited. Blood specimens were obtained from all AML patients at diagnosis, and 10 blood specimens were obtained on day 28 after induction chemotherapy. The controls also provided blood samples. Relative gene expression was quantified by PCR and determined using the comparative Ct method. Publicly available clinical data and gene expressions for 188 patients with AML were downloaded from TCGA data portal.
Compared with healthy controls, the expression of miRNA-181a-3p was significantly increased in patients with AML. MiR-181a-3p expression could be used to discriminate AML patients from controls, with up-regulated expression correlating with favorable prognosis. Moreover, miRNA-181a-3p expression was significantly decreased in patients who achieved a complete response after induction chemotherapy. The multivariate Cox analysis highlighted the prognostic value of miR-181a-3p for patients with AML. Finally, we found that miR-181a-3p expression was negatively correlated with the expression of the NF-κB essential modulator (NEMO/IKBKG).
MiR-181a-3p may be clinically useful as a disease marker for AML, and enhanced the prediction of patient outcomes to chemotherapy.
微小（mi）RNA在急性髓系白血病（AML）的发病机制和发展中起重要作用，其异常表达可能足以预测AML患者的预后和结局。我们评估了miRNA - 181a - 3p在预测AML患者预后和结局方面的临床诊断价值。
共招募了119例新诊断的成年AML患者和60例健康对照。在诊断时从所有AML患者获取血液标本，并在诱导化疗后第28天获取10份血液标本。对照也提供血液样本。通过PCR定量相对基因表达，并使用比较Ct法进行测定。从TCGA数据门户下载了188例AML患者的公开可用临床数据和基因表达。
与健康对照相比，AML患者中miRNA - 181a - 3p的表达显著增加。MiR - 181a - 3p表达可用于区分AML患者和对照，表达上调与良好预后相关。此外，诱导化疗后达到完全缓解的患者中miRNA - 181a - 3p表达显著降低。多变量Cox分析突出了miR - 181a - 3p对AML患者的预后价值。最后，我们发现miR - 181a - 3p表达与NF - κB必需调节因子（NEMO/IKBKG）的表达呈负相关。
MiR - 181a - 3p可能作为AML的疾病标志物具有临床应用价值，并增强了对患者化疗结局的预测。
